This company has shut down. Ascend Gene & Cell Therapies is no longer operating — its last tracked round was a Series A in 2023.
Explore the Startup GraveyardAscend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.
Ascend Gene & Cell Therapies has raised $65.9M in total funding. The most recent round was Series A. The last funding was announced in March 2023.
Ascend Gene & Cell Therapies's investors include DCVC Bio, Abingworth, Digitalis Ventures, 4BIO Capital, Petrichor Healthcare Capital Management.
Ascend Gene & Cell Therapies is headquartered in Potters Bar, United Kingdom.
Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.
Ascend Gene & Cell Therapies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Ascend Gene & Cell Therapies — Funding & Investors." VCBacked, March 20, 2023, https://www.vcbacked.co/company/ascend-gene-cell-therapies. Accessed August 6, 2026.
VCBacked. (2023). Ascend Gene & Cell Therapies — Funding & Investors. Retrieved August 6, 2026, from https://www.vcbacked.co/company/ascend-gene-cell-therapies
{{cite web |title=Ascend Gene & Cell Therapies — Funding & Investors |url=https://www.vcbacked.co/company/ascend-gene-cell-therapies |website=VCBacked |access-date=August 6, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated